What's Happening?
The University of Colorado Anschutz Medical Campus is developing a functional precision medicine platform aimed at personalizing treatments for rare cancers. Led by Alice Soragni, PhD, a professor of Biomedical Informatics and Neurosurgery and the Marsico
Chair in Excellence in Functional Precision Medicine, the initiative focuses on creating patient-derived tumor organoids. These miniature 'tumor avatars,' grown from a patient's own tumor cells, are used to test responses to various drugs. The platform, detailed in Nature Protocols, utilizes label-free imaging and artificial intelligence to continuously track individual organoid responses, identifying differences that conventional methods might miss. The goal is to integrate this organoid testing into clinical care, moving it from a research tool to a validated clinical assay that can inform treatment decisions for patients with hard-to-treat tumors. This approach is particularly crucial for rare cancers, where standard treatments are often non-existent due to a lack of sufficient data.
Why It's Important?
This advancement in functional precision medicine at CU Anschutz holds significant importance for cancer treatment, especially for patients with rare cancers who currently have limited options. By enabling the testing of hundreds of drugs and combinations on patient-specific tumor organoids, the platform can identify effective treatments that would otherwise remain unknown. This personalized approach moves beyond a 'one-size-fits-all' model, offering the potential for safer and more effective drug therapies. The integration of this technology into clinical laboratory infrastructure means that physicians could soon use this data alongside molecular and clinical information to make informed treatment decisions. This could lead to improved outcomes for patients, reduce unnecessary toxicity from ineffective treatments, and provide valuable insights into cancer recurrence and treatment resistance for all cancer types, not just rare ones.
What's Next?
Dr. Soragni's lab is actively working to transition the organoid platform from research to clinical application. This involves building the necessary infrastructure and validating the organoid assay for implementation within the Colorado Center for Personalized Medicine's (CCPM) CLIA-certified, CAP-accredited clinical laboratory. Once validated, the results from these assays can be reported clinically, allowing physicians to use the findings to support treatment decisions. The initiative is starting with a streamlined version of a one-week-turnaround mini-ring organoid assay. In the long term, the data derived from this screening platform, combined with DNA and RNA sequencing and other molecular characterizations, is expected to help identify new biomarkers for drug responses, potentially leading to simpler tests and better medicines for a broader patient population.
Beyond the Headlines
The development of this organoid platform at CU Anschutz represents a deeper shift towards truly personalized medicine, where treatment is tailored to the unique biological characteristics of each patient's tumor. This approach not only offers hope for patients with rare and difficult-to-treat cancers but also highlights the ethical imperative to move scientific discoveries from the lab to the patient's bedside as quickly and efficiently as possible. The use of AI and advanced imaging in this process underscores the growing role of technology in revolutionizing healthcare. Furthermore, the focus on understanding individual tumor responses could lead to a more nuanced understanding of cancer biology, potentially uncovering mechanisms of resistance and recurrence that are currently poorly understood, thereby benefiting future cancer research and treatment strategies across the board.
